Market Signal Briefing

The chip designer is set to be a prime beneficiary of the artificial intelligence (AI) boom.

Shares of Advanced Micro Devices (AMD +7.69%) climbed on Wednesday after Wall Street analysts issued favorable commentary on the chipmaker's prospects.

By the close of trading, AMD's stock price was up more than 7%.

Image source: Getty Images.

Getting more bullish KeyBanc analyst John Vinh expects AMD's sales and profits to surpass consensus estimates when it reports its fourth-quarter financial results on Feb. 3.

Vinh highlighted the robust demand for AMD's Turin data center central processing units (CPUs). Vinh believes sales are so strong that AMD is already almost sold out of server CPUs for 2026. AMD, in turn, could elect to raise prices by as much as 15% as cloud computing giants rush to secure their chip supplies.

Today's Change

(

7.69

%) $

17.84

Current Price

$

249.76

However, Vinh says some investors still question whether AMD can compete effectively with larger rival Nvidia in the advanced graphics processing unit (GPU) arena. Vinh says comments from management on AMD's upcoming conference call regarding customer wins and production schedules could help to assuage these concerns.

AI-driven gains Bernstein analyst Stacy Rasgon is also growing more optimistic about AMD's server-related business and upcoming Q4 report. Rasgon thinks sales of AMD's high-performance Epyc processors could surge by 30% in 2026.

Notably, Rasgon expects AMD's artificial intelligence (AI)-related sales to benefit from its partnership with OpenAI beginning in the second half of the year.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool has a disclosure policy.

Northern Star Resources Limited (NESRF) Q2 2026 Earnings Call January 21, 2026 5:00 PM EST

Company Participants

Stuart Tonkin - CEO, MD & Director
Simon Jessop - Chief Operating Officer
Ryan Gurner - Chief Financial Officer

Conference Call Participants

Levi Spry - UBS Investment Bank, Research Division
Ben Lyons - Jarden Limited, Research Division
Hugo Nicolaci - Goldman Sachs Group, Inc., Research Division
Matthew Frydman - MST Financial Services Pty Limited, Research Division
Daniel Morgan - Barrenjoey Markets Pty Limited, Research Division
Milan Tomic - JPMorgan Chase & Co, Research Division
Adam Baker - Macquarie Research
Mitch Ryan - Jefferies LLC, Research Division

Presentation

Operator

Thank you for standing by, and welcome to the Northern Star December 2025 Quarterly Results Call. [Operator Instructions]. I would now like to hand the conference over to Mr. Stuart Tonkin, Managing Director and CEO. Please go ahead.

Stuart Tonkin
CEO, MD & Director

Good morning, and thank you for joining us today. With me on the call is the Chief Financial Officer, Ryan Gurner; and Chief Operating Officer, Simon Jessop. As previously announced in the December quarter, gold sold totaled 348,000 ounces at an all-in sustaining cost of AUD 2,937 per ounce.

A number of one-off operational events across our assets resulted in this softer performance and required us to revise FY '26 production and cost guidance. With these events behind us, our team remains firmly focused on driving productivity improvements and strengthening cost discipline to deliver a stronger second half for our shareholders. Our FY '26 outlook provides revised guidance of 1.6 million to 1.7 million ounces of gold sold at an all-in sustaining cost of $2,600 to $2,800 an ounce.

Today, we also provide further detail for production and AISC guidance by production center. In addition, we have updated our capital expenditure forecast across the portfolio. Operational growth capital guidance remains unchanged at $1.14

-

Fourteenth year of recognition as a Top 100 Global Innovator for outstanding intellectual property

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has been recognized as one of the Clarivate Top 100 Global Innovators 2026 by Clarivate Plc, a global information services company based in the United Kingdom. Mitsubishi Electric’s achievements in the field of intellectual property (IP) continue to be highly recognized, as evidenced by being named a Global Innovator for the 14th time. The company was ranked in 17th place overall this year.

The award, which was established in 2012, is based on patent-related data collected by Clarivate. Candidates are companies and organizations that have filed at least 500 patent applications since 2000 and have more than 100 inventions registered as patents in the five-year period between 2020 and 2024. Four criteria—influence, success rate, geographic investment and rarity—are evaluated to select and honor the top 100 companies worldwide each year.

Mitsubishi Electric, which strategically positions IP as a crucial business resource for its future growth and development, carefully aligns IP activities with the company’s business and R&D strategies. In October 2021, the company launched Open Technology BankTM activities to promote external collaboration aimed at realizing a sustainable future by leveraging IP.

For the full text, please visit: www.MitsubishiElectric.com/news/

More News From Mitsubishi Electric Corporation

Back to Newsroom

Approximately 3,300 CenterPoint employees and contract workers supporting storm preparation and potential restoration efforts across Houston and parts of Southeast Texas

State of Texas emergency response resources activated ahead of potential impacts

ERCOT Weather Watch issued for Saturday to Tuesday; grid conditions expected to be normal

Customers urged to have a plan and prepare now for freezing temperatures, high winds and potential ice accumulation

, /PRNewswire/ -- To support its customers and communities, and following several days of actively preparing for this weekend's forecasted severe winter weather system, CenterPoint Energy secured over 600 additional frontline workers for an expanded workforce of 3,300 workers to address the approaching winter storm. Additionally, the company is standing up three staging sites Thursday at strategic locations across the northern portion of the Greater Houston area to pre-position resources to support potential restoration efforts.

In addition to CenterPoint's Emergency Operations Center staff of 200 personnel and on-system workforce of approximately 2,500 internal line workers, local contractors and vegetation management resources, the company has secured an additional approximately 600 frontline workers including more line workers, vegetation management resources, and damage assessors. The company's Emergency Operations Center was activated this morning and will remain activated through the weekend as CenterPoint continues executing its cold weather action plan.

CenterPoint continues to work closely with government officials and emergency agencies to prepare for the approaching winter weather system and continues to diligently monitor weather models and deploy cold weather mitigations across its electric and gas infrastructure.

"We know how important it is for homes and businesses to have the electric and natural gas service they expect and deserve, especially when severe weather is forecasted to impact our region. Our teams are mobilized across the area now, performing pre-storm checks, conducting additional tree trimming, and preparing to respond to any impacts on our system from the forecasted winter weather conditions, including icy weather, strong winds, and wintry precipitation. We will remain alert and continue to coordinate with local officials, and we urge our customers to stay weather alert, take steps to prepare now and have an emergency plan in place," said Don Daigler, CenterPoint's Senior Vice President, Emergency Preparedness and Response.

Staging sites
The company's three staging sites will be strategically placed, with two located across the northern portion of CenterPoint's Greater Houston service area where impacts are forecasted at this time to be the strongest. The staging sites will host the approximately 3,300 workers and help pre-position crews, vehicles, equipment and materiel needed for restoration across its service territory to be able to respond to service issues safely and as quickly as possible.

Cold weather preparations
The company is prepared to respond to cold weather and has performed a series of proactive pre-winter preparedness actions to strengthen and winterize its electric and natural gas infrastructure across Texas, as well as inspect and test cold-weather critical equipment ahead of potential severe cold weather. CenterPoint is also actively working plans to mobilize emergency response resources and coordinating with relevant local emergency responders and government officials in preparation. 

The pre-winter safety and readiness actions taken by CenterPoint include:

Activating its Emergency Operations Center to coordinate response and restoration efforts; Coordinating with the Public Utility Commission of Texas and the Electric Reliability Council of Texas (ERCOT) about statewide energy needs; Communicating with customers to provide safety and preparedness information directly via email and help keep customers informed and prepared; Conducting outreach to critical care customers by email, phone or text; Inspecting and testing critical electric equipment, including all 270 electric substations, executing enhanced tree trimming and conducting inspections to prepare for wintery precipitation and cold temperatures; Positioning Compressed Natural Gas (CNG) trucks at 14 strategic locations to be deployed to supplement the natural gas system, if needed; Monitoring more than 100 weather stations across the Greater Houston area to enhance situational awareness and storm preparation; Donated and installed more than 20 emergency backup generators at key locations across Greater Houston to improve local emergency preparedness and response efforts; and Conducted more than 19,000 total hours of emergency training in 2025 for hundreds of operational, emergency response and other personnel and contractors to strengthen severe weather preparation and response efforts. The current weather forecast for CenterPoint's Houston electric service territory indicates the potential for ice accumulation this weekend, subject to updated forecasts. The company reminds customers and community members to always assume downed lines or wires are energized and potentially dangerous if contacted. Stay at least 35 feet away from downed power lines or fallen wires and keep a safe distance from objects touching downed lines (tree limbs, vehicles, fences, etc.) and immediately report downed power lines to CenterPoint. 

Supporting community preparedness
As part of its ongoing commitment to supporting community preparedness and resilience, the CenterPoint Energy Foundation awarded a $1 million, five‑year grant to The Salvation Army last year to support disaster response capabilities across the Greater Houston area. This grant supports operations at The Salvation Army's Multi‑Purpose Distribution Center in Houston, a critical regional hub that coordinates emergency relief efforts and delivers essential services to vulnerable populations — including families, youth, seniors, and individuals experiencing homelessness — during hurricanes and other severe weather events. Funded separately and financially independent from the utility, the CenterPoint Energy Foundation continues to serve as a catalyst for good by leveraging its resources to enhance the safety, resilience and vibrancy of the communities CenterPoint Energy serves. Learn more at CenterPointEnergy.com/Foundation.

Stay informed with Power Alert Service®
CenterPoint electric customers are encouraged to enroll in the company's Power Alert Service® to receive winter storm outage details, estimated restoration times and customer-specific restoration updates by phone call, text or email.

Have a plan and stay safe
CenterPoint encourages customers to prepare and have a plan to stay safe during severe winter weather. Customers can get storm-related safety tips at CenterPointEnergy.com/ActionCenter — available in English, Spanish and Vietnamese.

Customers can also stay up to date on outages with CenterPoint's Outage Tracker, available in English and Spanish. The Outage Tracker is built to handle increased traffic during storms, is mobile-friendly, accessible for those with disabilities and allows customers to see outages by county, city and zip code.

For the latest updates, follow CenterPoint on X and visit CenterPointEnergy.com/ActionCenter. 

About CenterPoint Energy, Inc.
As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota, Ohio and Texas. As of September 30, 2025, the company owned approximately $45 billion in assets. With approximately 8,300 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

For more information, contact:
Communications
[email protected]

SOURCE CenterPoint Energy

Shares of Rocket Lab went parabolic last year, but can the stock continue soaring?

Last year, shares of space exploration company Rocket Lab (RKLB 1.64%) soared by 174% -- making it one of the standout stocks on the Nasdaq Composite.

While this type of momentum may seem overpronounced, Rocket Lab's rally was validated by an improving financial profile and changing perception of the company's business model.

Let's dig into Rocket Lab's milestone 2025 and assess what could be in store for this year. While the company remains one of the hottest growth stocks outside of artificial intelligence (AI), smart investors understand that nothing goes up in a straight line forever.

Image source: Getty Images.

Rocket Lab had an impressive 2025 Rocket Lab is not just a launch business. The company operates across various aspects of the space value chain, including designing services and manufacturing spacecraft components. While the space economy remains a relatively niche market, Rocket Lab's diversified business model is gaining traction.

Through the first nine months of 2025, the company generated $422 million in revenue -- representing an increase of 39% year over year. In addition, Rocket Lab's gross profit has nearly doubled -- growing from $79 million to $140 million as of the third quarter.

On top of that, the company's backlog of $510 million has grown by 56% over the last year -- providing Rocket Lab with much-needed revenue and cost planning visibility.

The one slight blemish on the company's financial profile is profitability. Launching and designing rockets and satellites is extremely capital-intensive and time-consuming. Given the lag between Rocket Lab building its products, winning contracts, and actually recognizing revenue, it's not surprising to learn the company remains unprofitable.

Nevertheless, during the third quarter, Rocket Lab reported a narrower loss per share of ($0.03) compared to ($0.10) during the same period in 2024.

Today's Change

(

-1.64

%) $

-1.46

Current Price

$

87.70

What caused Rocket Lab stock to soar last year? Given the company's improving financial profile and ability to secure additional contracts across the public and private sectors, Rocket Lab's rising valuation could suggest that more investors are beginning to buy into the broader space exploration thesis.

As it pertains to Rocket Lab specifically, I think "smart money" is starting to see Rocket Lab as a vertically integrated player fueling space infrastructure -- touching everything from rocket launches, satellite components, and specialized manufacturing. In essence, Rocket Lab sits at a unique intersection of aerospace, defense contracting, and private sector space exploration.

Outside of its business results, however, sits another tangential catalyst for Rocket Lab. Potentially the most obvious, or at least most cited, comparable business to Rocket Lab is Elon Musk's SpaceX.

At the end of 2024, SpaceX was valued at $350 billion. However, in July, the company completed a tender offer that valued SpaceX at a reported $400 billion. Just months later, SpaceX subsequently completed a secondary sale that pushed the company's valuation to $800 billion. Notably, these deals took place as rumors swirled about a potential SpaceX IPO in 2026.

RKLB data by YCharts

Between SpaceX's two transactions, shares of Rocket Lab soared 103%. Now, to be clear, I'm not saying that the news around SpaceX fueled some sort of meme-induced rally in Rocket Lab stock.

What I am saying, though, is that SpaceX's popularity could, in some ways, validate the highly speculative commercial space market. In turn, Rocket Lab began attracting additional capital in hopes of finding the "next SpaceX."

Is Rocket Lab a good buy for 2026? So here's the big question: Why am I anticipating Rocket Lab will return from orbit in 2026?

It all has to do with a recent interview I watched. There is a popular business podcast on YouTube called All-In, which features four entrepreneurs and Silicon Valley veterans. One of them is a former employee of both AOL and Facebook (now Meta Platforms), named Chamath Palihapitiya.

During a recent episode, Palihapitiya revealed that his contrarian investment idea for 2026 is that SpaceX will not go public. Instead, he thinks the company will reverse merge into Tesla.

First thing's first -- do not get overwhelmed by the term "reverse merger," it's just fancy finance jargon. Essentially, a reverse merger allows a private company to go public by merging with an existing public company rather than going through the traditional IPO underwriting process.

What Chamath is explaining here is really nuanced. He's not suggesting that SpaceX won't go public. He's saying that the company will merge with Tesla, creating a giant holding company for Musk's two most influential creations.

In my opinion, Palihapitiya could be spot-on here. Musk has long refrained from taking SpaceX public. In fact, the serial entrepreneur has expressed a vision to control Tesla, SpaceX, and xAI under one roof for quite some time -- stitching together his ambitions among sustainable energy, autonomous systems, batteries, AI, and the final frontier.

Should Musk pursue this avenue, Rocket Lab investors don't have anything to worry about. Rocket Lab's business profile is improving, and the company certainly has a lot of catalysts.

If SpaceX does not IPO in 2026, investors could see some waning enthusiasm in adjacent players such as Rocket Lab. This would be purely an emotional reaction, not rooted in business fundamentals.

Against this backdrop, I do not think Rocket Lab stock is a prudent buy given its run-up over the last year. Risk-tolerant investors with a stomach for volatility could consider a position in Rocket Lab. But for those seeking more durable opportunities, I would wait for a pullback in Rocket Lab before buying.

New York, New York--(Newsfile Corp. - January 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bitdeer Technologies Group (NASDAQ: BTDR) between June 6, 2024 and November 10, 2025, both dates inclusive (the "Class Period"), of the important February 2, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Bitdeer securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Bitdeer class action, go to https://rosenlegal.com/submit-form/?case_id=49102 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning Bitdeer's research and technology roadmap for its SEALMINER Bitcoin mining machine. Defendants' statements included, among other things, confidence in Bitdeer's mass production of its fourth-generation SEALMINER (A4) rigs using its SEAL04 ASIC ("application-specific integrated circuit") chip technology expected to have a chip energy efficiency of as low as 5J/TH. Defendants provided these positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concerning material adverse facts concerning the true state of Bitdeer's SEALMINER A4 project. Specifically, defendants failed to disclose that the SEAL04 chip projected to have a chip-level energy efficiency of 5 J/TH would be ready for use in the A4 rigs with an expected mass production to begin in the second quarter 2025. Such statements absent these material facts caused investors to purchase Bitdeer securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Bitdeer class action, go to https://rosenlegal.com/submit-form/?case_id=49102 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281154

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ITUB,NU,VALE,BOLSY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

January 21, 2026 22:30 ET  | Source: BioAge Labs, Inc.

EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 884,615 shares of common stock in connection with the offering. All of the shares of common stock are being offered by BioAge.

Goldman Sachs & Co. LLC, Piper Sandler and Citigroup are acting as joint book-running managers for the offering.

BioAge intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund research, clinical and process development and manufacturing of its product candidates, including BGE-102 and further development of its NLRP3 and APJ programs, working capital, capital expenditures, reduction of indebtedness and for other general corporate purposes.

The shares are being offered by BioAge pursuant to a registration statement on Form S-3 (No. 333-290688) that became effective on November 25, 2025. A preliminary prospectus supplement and accompanying prospectus relating to this offering have been filed with the Securities and Exchange Commission (the “SEC”). Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, and when available, the final prospectus supplement, may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or via email at [email protected]; or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of BioAge, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding expectations of market conditions, timing of the closing, the satisfaction of customary closing conditions related to the offering and the anticipated gross proceeds of the offering and the use thereof. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive interim results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading “Risk Factors” included in BioAge’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 6, 2025, and BioAge’s other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts
PR: Chris Patil, [email protected] 
IR: Dov Goldstein, [email protected] 
Partnering: Peng Leong, [email protected] 

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

January 21, 2026 20:54 ET  | Source: Erasca, Inc.

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $225.0 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 3,375,000 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on January 23, 2026, subject to the satisfaction of customary closing conditions.

Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.

J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering.

The securities described above are being offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) and was declared effective on August 22, 2025.

A preliminary prospectus supplement relating to this offering has been filed with the SEC and a final prospectus supplement relating to this offering will be filed with the SEC. The offering may be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected]. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Forward Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the expected closing of the offering and the anticipated use of proceeds therefrom. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]

Source: Erasca, Inc.

Kinder Morgan, Inc. (KMI) Q4 2025 Earnings Call January 21, 2026 4:30 PM EST

Company Participants

Richard Kinder - Executive Chairman of the Board
Kimberly Dang - CEO & Director
Thomas Martin - President
David Michels - VP & CFO
Sital Mody - VP & President of Natural Gas Pipelines

Conference Call Participants

Julien Dumoulin-Smith - Jefferies LLC, Research Division
Jacqueline Koletas - Goldman Sachs Group, Inc., Research Division
Theresa Chen - Barclays Bank PLC, Research Division
Michael Blum - Wells Fargo Securities, LLC, Research Division
Jeremy Tonet - JPMorgan Chase & Co, Research Division
Jean Ann Salisbury - BofA Securities, Research Division
Keith Stanley - Wolfe Research, LLC
Manav Gupta - UBS Investment Bank, Research Division
Jason Gabelman - TD Cowen, Research Division

Presentation

Operator

Good afternoon, and thank you for standing by, and welcome to the Fourth Quarter 2025 Earnings Results Conference Call. [Operator Instructions] Today's conference is being recorded. If you have any objections, you may disconnect at this time. It is now my pleasure to turn the call over to Mr. Rich Kinder, Executive Chairman of Kinder Morgan.

Richard Kinder
Executive Chairman of the Board

Thank you, Michelle. Before we begin, as usual, I'd like to remind you that KMI's earnings release today and this call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities and Exchange Act of 1934 as well as certain non-GAAP financial measures. Before making any investment decisions, we strongly encourage you to read our full disclosures on forward-looking statements and use of non-GAAP financial measures set forth at the end of our earnings release as well as review our latest filings with the SEC for important material assumptions, expectations and risk factors that may cause actual results to differ materially from those anticipated and described in such forward-looking statements.

I have only

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds persons who invested in securities of SLM Corporation a/k/a Sallie Mae (NASDAQ: SLM) between July 25, 2025 and August 14, 2025, both dates inclusive (the “Class Period”), of the important February 17, 2026 lead plaintiff deadline.

SO WHAT: If you purchased SLM securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SLM class action, go to https://rosenlegal.com/submit-form/?case_id=49601 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 17, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) SLM was experiencing a significant increase in early stage delinquencies; (2) accordingly, defendants overstated the effectiveness of SLM’s loss mitigation and/or loan modification programs, as well as the overall stability of SLM’s private education loan (“PEL”) delinquency rates; and (3) as a result, defendants’ public statements made a materially false and misleading impression regarding SLM’s business, operations, and prospects at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the SLM class action, go to https://rosenlegal.com/submit-form/?case_id=49601 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Constellation Energy is well positioned to benefit from the rise of artificial intelligence (AI) in the U.S.

Nuclear energy stocks were among the energy sector's best-performing stocks in 2025.

Oklo, for instance, ended the year with a triple-digit gain, while uranium enricher Centrus Energy and uranium miner Cameco both had blockbuster performances.

Even the VanEck Uranium and Nuclear ETF (NLR +2.86%), a nuclear energy exchange-traded fund, ended the year with a 12-month gain of more than 50%.

One company that continues to stand out for its dominance in the industry is Constellation Energy (CEG 0.35%). Indeed, if I had to pick one nuclear energy stock to buy and hold for the next 10 years, Constellation would top the list. Here's why.

Image source: Getty Images.

A nuclear advantage that can't be replicated quickly Constellation Energy may not have the exciting growth potential of a start-up like Oklo. But it has something Oklo doesn't have yet, nor will likely have for several years: operating nuclear power plants.

Indeed, Constellation operates the largest nuclear fleet in the U.S., and it has signed several contracts that will extend over the next decade.

Today's Change

(

-0.35

%) $

-1.03

Current Price

$

294.37

In June 2025, it announced a 20-year agreement with Meta Platforms tied to the full output of its Clinton Clean Energy Center starting in 2027. It has also made moves to restart the former Three Mile Island Unit 1 site (now Crane Clean Energy Center) with support from Microsoft.

Constellation has also completed its acquisition of Calpine, which makes it the U.S.'s largest producer of electricity.

Looking ahead, I wouldn't rule out the possibility of Constellation developing its own next-generation reactors. Like Oklo and NuScale, which are designing small reactors, Constellation could develop its own novel technology to keep up with demand from artificial intelligence (AI) data centers. In fact, CEO Joe Dominguez has already signaled that the company might consider next-generation nuclear plants on existing sites.

Again, Constellation likely won't deliver a start-up-style upside over a 10-year period. But with operating assets and long-term contracts, it look well positioned to grow over the next decade.

Steven Porrello has positions in Microsoft and Oklo. The Motley Fool has positions in and recommends Cameco, Constellation Energy, Meta Platforms, and Microsoft. The Motley Fool recommends NuScale Power and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

New York, New York--(Newsfile Corp. - January 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds persons who invested in securities of SLM Corporation a/k/a Sallie Mae (NASDAQ: SLM) between July 25, 2025 and August 14, 2025, both dates inclusive (the "Class Period"), of the important February 17, 2026 lead plaintiff deadline.

SO WHAT: If you purchased SLM securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SLM class action, go to https://rosenlegal.com/submit-form/?case_id=49601 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 17, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) SLM was experiencing a significant increase in early stage delinquencies; (2) accordingly, defendants overstated the effectiveness of SLM's loss mitigation and/or loan modification programs, as well as the overall stability of SLM's private education loan ("PEL") delinquency rates; and (3) as a result, defendants' public statements made a materially false and misleading impression regarding SLM's business, operations, and prospects at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the SLM class action, go to https://rosenlegal.com/submit-form/?case_id=49601 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281209

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ACN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of F5, Inc. (NASDAQ: FFIV) between October 28, 2024 and October 27, 2025, both dates inclusive (the "Class Period"), of the important February 17, 2026 lead plaintiff deadline.

So What: If you purchased F5 securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the F5 class action, go to https://rosenlegal.com/submit-form/?case_id=46672 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 17, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to F5's projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. In truth, F5's optimistic claims, touting its purported best-in-industry security and overall emphasis and confidence in F5's ability to meet and capitalize on the growing security needs for its clientele fell short of reality; F5 was, at the time, the subject of a significant security incident, placing its clientele's security and F5's future prospects at significant risk. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the F5 class action, go to https://rosenlegal.com/submit-form/?case_id=46672 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Short position through short-selling of the stock, or purchase of put options or similar derivatives in PKW over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in SLM to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in SLM between July 25, 2025 and August 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - January 21, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SLM Corporation ("SLM" or the "Company") (NASDAQ: SLM) and reminds investors of the February 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) SLM was experiencing a significant increase in early stage delinquencies; (2) accordingly, Defendants overstated the effectiveness of SLM's loss mitigation and/or loan modification programs, as well as the overall stability of the Company's PEL delinquency rates; and (3) as a result, Defendants' public statements made a materially false and misleading impression regarding SLM's business, operations, and prospects at all relevant times.

On August 14, 2025, investment bank TD Cowen issued a report addressing SLM, flagging that, "overall, July [2025] delinquencies were up 49 bp m/m, higher (worse)than the seasonal (+10 bps) performance for July, driven by a 45 bps increase in early stage delinquencies." Notably, TD Cowen's findings directly contradicted Defendant Graham's assurances-made late in the month of July 2025-that Defendants were observing delinquency rates that "really are following the normal seasonal trends we would expect in the business."

Following TD Cowen's report, SLM's stock price fell $2.67 per share, or 8.09%, to close at $30.32 per share on August 15, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding SLM's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the SLM Corporation class action, go to www.faruqilaw.com/SLM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281157

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Daniel Baker
CEO, President & Director

Good afternoon, and welcome to the NVE Corporation Conference Call for the quarter ended December 31, 2025. I'm Dan Baker, NVE's President and CEO. I'm joined by Daniel Nelson, our Principal Financial Officer; and Pete Eames, Vice President of Advanced Technology.

This call is being webcast live via YouTube and Amazon Chime and being recorded. A replay will be available through our website, nve.com, and our YouTube channel, youtube.com/nvecorporation. [Operator Instructions]

After my opening comments, Daniel Nelson will present our financial results. Pete will cover new products and R&D. I'll cover sales and marketing and then we'll open the call to questions. We issued our press release with financial results and filed our quarterly report on Form 10-Q in the past hour following the close of market. Links to the press release and 10-Q are available through our website, the SEC's website and X, formerly known as Twitter.

Please refer to the safe harbor statement on your screen. Comments we may make that relate to future plans, events, financial results or performance are forward-looking statements that are subject to certain risks and uncertainties, including, among others, such factors as uncertainties related to the economic environments in the industries we serve, risks and uncertainties related to future sales and revenue and risks and uncertainties related to tariffs, customs duties and other trade barriers as well as the risk factors listed from time to time in our filings with the SEC, including our annual report on Form 10-K for the year ended March 31, 2025, as updated in

HomeStock IdeasLong IdeasHealthcare 

SummaryAlvotech remains my favorite in the biosimilars market, which is expected to reach $151.6 billion by 2033.It already has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea.Even though it received three CRLs in Q4, Alvotech expects its revenue to be between $650 million and $700 million in 2026, up 37.2% from 2024.Also, according to Seeking Alpha, the average PT for it is $22.17, which implies an upside of about 351% from ALVO's current stock price.Thus, I continue to cover Alvotech with a 'Strong Buy' rating. Edwin Tan/E+ via Getty Images

Since my October article, "My 5 Biggest Biotech Stocks Big Pharma Can Buy Now", Alvotech stock (ALVO) has fallen 44%, underperforming the S&P 500 [2.2% return] (SPY).

This drop was primarily due to Alvotech

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ALVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

-

NEW YORK--(BUSINESS WIRE)--BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, announced today the pricing of its initial public offering of an aggregate of 11,821,595 shares of Class A common stock at a price to the public of $18.00 per share. The offering consists of 11,026,365 shares of Class A common stock being offered by BitGo and 795,230 shares of Class A common stock being offered by certain existing stockholders of BitGo. BitGo will not receive any proceeds from the sale of the shares by the selling stockholders in connection with the offering. In connection with the offering, BitGo has granted the underwriters a 30-day option to purchase up to an additional 1,770,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on the New York Stock Exchange on January 22, 2026 under the ticker symbol "BTGO" and the offering is expected to close on January 23, 2026, subject to customary closing conditions.

Goldman Sachs & Co. LLC is acting as lead book-running manager for the proposed offering. Citigroup is acting as book-running manager. Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Keefe, Bruyette & Woods, A Stifel Company, Canaccord Genuity and Cantor are also acting as book-running managers. Clear Street, Compass Point, Craig-Hallum, Rosenblatt, Wedbush Securities and SoFi are acting as co-managers.

A registration statement relating to these securities was declared effective by the United States Securities and Exchange Commission (the “SEC”) on January 21, 2026. The offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, when available, copies of the preliminary prospectus relating to the proposed offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected] and Citigroup, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About BitGo
BitGo is the digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. Since 2013, BitGo has focused on accelerating the transition of the financial system to a digital asset economy. BitGo maintains a global presence and multiple regulated entities, including BitGo Bank & Trust, National Association, a federally chartered digital asset bank. Today, BitGo serves thousands of institutions, including many of the industry's top brands, financial institutions, exchanges, and platforms, and millions of investors worldwide.

More News From BitGo Holdings, Inc.

Back to Newsroom

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Wealthfront To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Wealthfront stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - January 21, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Wealthfront Corporation ("Wealthfront" or the "Company") (NASDAQ: WLTH).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Shares of Wealthfront Corporation declined sharply following the company's first post-IPO earnings release, pressured by disappointing asset flow figures and emerging investor concerns about strategic exposures underpinning its mortgage business. The stock sell-off came as Wealthfront reported softer net inflows in recent months, signaling a slowdown in client acquisitions and cash management balances relative to prior periods. Additionally, heightened market scrutiny over the CEO's ownership stake in a banking partner central to the firm's mortgage initiative has added to investor uncertainty, fueling speculation around potential conflicts of interest and long-term integration risks.

Since the company's IPO on or around December 12, 2025, at $14.00 per share, the stock has fallen $3.74, or 26.71%, to close at $10.26 on January 14, 2026.

To learn more about the Wealthfront investigation, go to www.faruqilaw.com/WLTH or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281159

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Matt Dolgin says investors are repricing the stock after the company's guidance underwhelmed in its latest earnings report. That said, he sees the reset as necessary for long-term stock expectations.

The banking giant in Latin America is growing quickly.

Over the last few decades, banking in the United States has gone digital. The same transition is now happening in Latin America, and it is being driven by one company above all else: Nu Holdings (NU +1.59%). The digital banking mobile app is disrupting the stodgy legacy institutions in Brazil and Mexico, and now has over 100 million customers, making it larger by customer count than every bank in the United States.

The stock has soared over the last year, but still trades below $18 as of this writing on Jan. 20, 2026. Does that make it a buy right now?

Today's Change

(

1.59

%) $

0.27

Current Price

$

17.24

Rising revenue, declining per-customer costs Given the aggressively punitive business models of legacy banks in places such as Mexico and Brazil, Nu Bank has easily been able to win customers to its digital-only banking solution. Instead of charging high fees on cash withdrawals, making customers wait hours in line at branches, and utilizing frustratingly slow technology solutions, Nu Bank has built a customer friendly banking app.

Unsurprisingly, this has led to the wide adoption of its financial services products. Customers now number 110 million in Brazil and 13 million in Mexico, with the latter growing at an exponential rate. Colombia is also seeing wide adoption, but it will be less important for the Nu Holdings business given its smaller economy.

At the same time it is adding a massive amount of customers, Nu Bank is also growing its revenue per customer while decreasing per-customer costs. Average revenue per active customer is now $12.50 in Mexico as of the latest quarter, compared to $5.20 in 2021. The cost per customer has gone from $3 to $1 as it gains greater scale.

This dynamic -- which is also happening in Brazil -- is why Nu Holdings' net income has gone from breakeven to $2.5 billion within the last three years.

Image source: Getty Images.

Multiple new markets to tackle Even though Nu Bank has over 100 million customers today, it is only operating in three Latin American countries: Brazil, Mexico, and Colombia. These are the largest countries in the region by population, but it still leaves the business with many other markets to disrupt, with the total population of the greater region exceeding 600 million and growing.

Management has hinted it will soon enter new markets such as Chile, Argentina, or Peru. It also recently applied for a banking license in the United States, which could enable it to offer cross-border services to immigrants in the region, helping them connect with friends and family back home.

Overall, Nu Bank not only has room to significantly expand revenue per customer and customer count in Brazil, Mexico, and Colombia, but also a long runway to expand into new markets in North and South America. This gives the business outsize growth potential over the next decade.

NU Net Income (TTM) data by YCharts

Is Nu Holdings stock a buy today? Today, Nu Holdings trades at a market cap of $81 billion and a price-to-earnings ratio (P/E) of 32.4, based on trailing net income of $2.5 billion.

While expensive for a banking stock, this may prove cheap for investors who hold for the next decade. Nu Holdings has the opportunity to significantly grow its top-line revenue through new customer acquisition and by layering on additional financial services, such as credit cards. At the same time, it is decreasing its cost per customer, which should help its profit margin grow.

It wouldn't be surprising if, five years from now, Nu Holdings is generating $10 billion in annual net income, especially once it tones down its major customer acquisition spending. That would give the stock a P/E of 8 based on the current stock price, which looks cheap even on a five-year forward basis.

Don't think Nu Holdings is a stock to avoid after rising close to 50% in the past year. Shares still look cheap for long-term investors at $18 or below right now.

A view of the Valero Houston Refinery in Houston, Texas, U.S., June 23, 2025. REUTERS/Joel Angel Juarez Purchase Licensing Rights, opens new tab

CompaniesHOUSTON, Jan 21 (Reuters) - Valero (VLO.N), opens new tab bought a cargo of Venezuelan crude oil, two sources said on Wednesday, the first deal by a U.S. Gulf Coast refiner struck as part of Washington's deal with Caracas to buy up to 50 million barrels of the South American country's crude.

Valero bought the crude from trading house Vitol, one of the two sources said. The crude was traded for delivery to the U.S. Gulf Coast at a discount of about $8.50 to $9.50 to Brent crude , two sources said.

Sign up here.

While Valero has been a buyer of Venezuelan crude through Venezuelan state oil company's partner, Chevron (CVX.N), opens new tab, the deal would mark the first purchase from trading houses that were only authorized this month to market crude from Venezuela.

Offers of Venezuelan flagship Merey heavy crude to U.S. refiners began last week at a discount of between $6 and $7.50 per barrel to Brent.

Before sanctions were imposed in 2019, several large U.S. Gulf Coast refineries bought and processed about 800,000 barrels per day of Venezuela's heavy oil, according to U.S. government data.

Reporting by Georgina McCartney and Arathy Somasekhar in Houston; Editing by Himani Sarkar

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Houston-based energy reporter focused on oil markets and energy companies. Arathy closely tracks U.S. crude supply and its impact on global markets, ever changing crude oil flows, and reports on U.S. shale producers and oilfield service companies.